Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C. Herrington WG, et al. Among authors: von eynatten m. Clin Kidney J. 2019 Feb 11;13(4):722. doi: 10.1093/ckj/sfz009. eCollection 2020 Aug. Clin Kidney J. 2019. PMID: 32905262 Free PMC article.
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C. Herrington WG, et al. Among authors: von eynatten m. Clin Kidney J. 2018 Dec;11(6):749-761. doi: 10.1093/ckj/sfy090. Epub 2018 Oct 25. Clin Kidney J. 2018. PMID: 30524708 Free PMC article. Review.
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial.
Wanner C, Cooper ME, Johansen OE, Toto R, Rosenstock J, McGuire DK, Kahn SE, Pfarr E, Schnaidt S, von Eynatten M, George JT, Gollop ND, Marx N, Alexander JH, Zinman B, Perkovic V. Wanner C, et al. Among authors: von eynatten m. Clin Kidney J. 2021 Jul 14;14(9):2136. doi: 10.1093/ckj/sfab104. eCollection 2021 Sep. Clin Kidney J. 2021. PMID: 34476096 Free PMC article.
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.
Wanner C, Cooper ME, Johansen OE, Toto R, Rosenstock J, McGuire DK, Kahn SE, Pfarr E, Schnaidt S, von Eynatten M, George JT, Gollop ND, Marx N, Alexander JH, Zinman B, Perkovic V; CARMELINA investigators. Wanner C, et al. Among authors: von eynatten m. Clin Kidney J. 2021 Jan 17;14(1):226-236. doi: 10.1093/ckj/sfaa225. eCollection 2021 Jan. Clin Kidney J. 2021. PMID: 33564423 Free PMC article.
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
Wanner C, Inzucchi SE, Zinman B, Koitka-Weber A, Mattheus M, George JT, von Eynatten M, Hauske SJ; EMPA-REG OUTCOME Investigators. Wanner C, et al. Among authors: von eynatten m. Diabetes Obes Metab. 2020 Dec;22(12):2335-2347. doi: 10.1111/dom.14158. Epub 2020 Sep 10. Diabetes Obes Metab. 2020. PMID: 32744354
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI. Mayer GJ, et al. Among authors: von eynatten m. Kidney Int. 2019 Aug;96(2):489-504. doi: 10.1016/j.kint.2019.02.033. Epub 2019 Mar 21. Kidney Int. 2019. PMID: 31142441 Free article. Clinical Trial.
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, von Eynatten M, Zinman B, Inzucchi SE, Wanner C, Koitka-Weber A. Kraus BJ, et al. Among authors: von eynatten m. Kidney Int. 2021 Mar;99(3):750-762. doi: 10.1016/j.kint.2020.10.031. Epub 2020 Nov 10. Kidney Int. 2021. PMID: 33181154 Free article. Clinical Trial.
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators. Wanner C, et al. Among authors: von eynatten m. Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13. Circulation. 2018. PMID: 28904068 Clinical Trial.
133 results